◆ mixed
Impact
PhasePhase 2
Time to marketNo timeline is estimable. The drug is still at Phase 2 with no announced Phase 3 plan under Exicure. The program is being sold to GPCRT Inc., making any go-to-market timeline dependent on the buyer's development strategy.
GPC-100 burixafor Updated Nov 14
What to watch
Watch the November 16, 2026 interim payment deadline (KRW 2.0 billion) as a sign of deal commitment from GPCRT Inc., and the November 30, 2026 expected closing. If the deal closes, Exicure will have ~$4.8M cash but no operating assets. If it fails, Exicure faces a severe liquidity crunch with no pipeline and an active Nasdaq delisting notice.
Bull case
- GPC-100 (burixafor) showed positive Phase 2 topline data at the December 2025 ASH meeting, with nearly 90% stem cell mobilization in multiple myeloma patients, suggesting meaningful clinical activity.
- The KRW 6.5 billion (~$4.8M) asset sale to GPCRT Inc. provides a cash infusion worth roughly 80% of Exicure's market cap, potentially extending the company's runway.
- The drug's CXCR4 mechanism is a validated target for stem cell mobilization, similar to approved drugs like plerixafor (Mozobil).
Bear case
- Exicure is selling the GPC-100 program because it cannot fund further development; the company had only $3.7M in cash as of early 2026 and received a Nasdaq delisting notice in September 2026.
- After the sale closes, Exicure will have no active drug pipeline, raising going-concern and reverse-merger-or-liquidation risk.
- The company retains ~$1.4M in pre-September 2026 program liabilities (unpaid CRO fees of $644K and sublease obligations of $783K), and the deal could still fail to close.